Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib +/- Anti-PD-1 in Advanced HCC
NCT05282433Phase 2Unknown
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in hepatocellular carcinoma (HCC), sponsored by Zhongnan Hospital of Wuhan University. Status: unknown.
02
Drugs
surufatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05282433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282433.